OBSV ObsEva SA

2.12
-0.13  -6%
Previous Close 2.25
Open 2.32
Price To Book 1.93
Market Cap 94,535,229
Shares 44,592,089
Volume 213,640
Short Ratio
Av. Daily Volume 541,502
Stock charts supplied by TradingView

NewsSee all news

  1. ObsEva SA General Corporate Statement By Foreign Issuer (Form6) (0001564590-20-015504)

  2. ObsEva SA: New Date Announcement for AGM

    Geneva, Switzerland and Boston, MA – March 27, 2020 – ObsEva SA (NASDAQ:OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health today

  3. ObsEva Provides Update Related to COVID-19 Pandemic

      Patient safety remains the top priority PRIMROSE 1 and PRIMROSE 2 trial results expected to be announced in Q2:20, as planned PROLONG trial results expected to be announced in 2H:20, as planned New patient

  4. ObsEva SA Link to Annual Report 2019

      Geneva, Switzerland and Boston, MA – March 5, 2020 - ObsEva SA (NASDAQ:OBSV), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today reported

  5. ObsEva Announces Year End 2019 Financial Results and Business Update

      Primary endpoint achieved in 94% of women in linzagolix Phase 3 PRIMROSE 2 trial in uterine fibroids Linzagolix Phase 3 PRIMROSE 1 six-month primary endpoint results and PRIMROSE 2 twelve-month data expected in

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data met primary endpoint - December 9, 2019. 12 month data due 2Q 2020.
Linzagolix OBE2109 - PRIMROSE 2
Uterine fibroids
Phase 2a data due 2H 2020.
OBE022 - PROLONG
Pre-term labor
Phase 3 data released February 26,2018 - primary endpoint met. Improvement shown in ET D5 subgroup but not in ET D3.
OBE001 - IMPLANT2
IVF
Phase 3 data due 2Q 2020.
Linzagolix OBE2109 - PRIMROSE 1
Uterine fibroids
Phase 3 trial did not meet primary endpoint - November 10, 2019.
Nolasiban (OBE001) - IMPLANT 4
Improving IVF outcomes
Phase 3 initiation announced May 9, 2019. New patient screening and randomization on hold due to COVID-19 - noted March 22, 2020.
Linzagolix (OBE2109)- EDELWEISS 2
Endometriosis
Phase 3 initiation announced May 9, 2019. New patient screening and randomization on hold due to COVID-19 - noted March 22, 2020.
Linzagolix (OBE2109) - EDELWEISS 3
Endometriosis

Latest News

  1. ObsEva SA General Corporate Statement By Foreign Issuer (Form6) (0001564590-20-015504)

  2. ObsEva SA: New Date Announcement for AGM

    Geneva, Switzerland and Boston, MA – March 27, 2020 – ObsEva SA (NASDAQ:OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health today

  3. ObsEva Provides Update Related to COVID-19 Pandemic

      Patient safety remains the top priority PRIMROSE 1 and PRIMROSE 2 trial results expected to be announced in Q2:20, as planned PROLONG trial results expected to be announced in 2H:20, as planned New patient

  4. ObsEva SA Link to Annual Report 2019

      Geneva, Switzerland and Boston, MA – March 5, 2020 - ObsEva SA (NASDAQ:OBSV), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today reported

  5. ObsEva Announces Year End 2019 Financial Results and Business Update

      Primary endpoint achieved in 94% of women in linzagolix Phase 3 PRIMROSE 2 trial in uterine fibroids Linzagolix Phase 3 PRIMROSE 1 six-month primary endpoint results and PRIMROSE 2 twelve-month data expected in

  6. ObsEva SA to Hold Year End 2019 Financial Results and Business Update Conference Call on March 5, 2020

      Geneva, Switzerland and Boston, MA – February 27, 2020 - ObsEva SA (NASDAQ:OBSV), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced

  7. ObsEva SA to present at the SVB LEERINK 9th Annual Global Healthcare Conference February 26th 2020

    Geneva, Switzerland and Boston, MA – February 18, 2019 – ObsEva SA (NASDAQ:OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health today

  8. ObsEva to Outline Corporate Plans For 2020 and Beyond at JP Morgan Healthcare Conference in San Francisco

      Phase 3 linzagolix trials expected to generate additional data in uterine fibroids in Q2:20 with first linzagolix regulatory filing planned for late 2020Enrollment of linzagolix US and EU Phase 3 trials in

  9. ObsEva and Yuyuan BioScience Technology Announce Sublicense Agreement to Develop and Commercialize Nolasiban in the People's Republic of China

      Geneva, Switzerland, 13 January 2020 – ObsEva and Yuyuan BioScience Technology ("Yuyuan") today announced that they have entered into a sublicense agreement to develop and commercialize nolasiban for improving

  10. ObsEva SA to Participate in in JP Morgan Healthcare Conference January 13-16, 2020

    Geneva, Switzerland and Boston, MA – January 7, 2020 - ObsEva SA (NASDAQ:OBSV), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced that

  11. ObsEva Announces Positive Results from Uterine Fibroids Phase 3 Study (PRIMROSE 2) of Linzagolix

    Phase 3 trial (PRIMROSE 2) met primary and secondary efficacy endpoints93.9% responder rate for 200 mg with ABT (p < 0.001)56.7% responder rate for 100 mg without ABT (p < 0.001)Both doses achieved important

  12. ObsEva SA to Hold Conference Call to Discuss PRIMROSE 2 Trial Results on December 9, 2019

      Geneva, Switzerland and Boston, MA –December 6, 2019 - ObsEva SA (NASDAQ:OBSV), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced that

  13. ObsEva Announces Third Quarter 2019 Financial Results

    – Reports Update on Three Women's Health Product Candidates – – Focusing on Phase 3 Programs for Linzagolix and the Phase 2 Program for OBE022 – – Company to Host Conference Call/Webcast Today at 8 am ET/2pm CET

  14. ObsEva Announces Third Quarter 2019 Financial Results

    – Reports Update on Three Women's Health Product Candidates – – Focusing on Phase 3 Programs for Linzagolix and the Phase 2 Program for OBE022 – – Company to Host Conference Call/Webcast Today at 8 am ET/2pm CET

  15. Obseva Announces That Nolasiban Implant 4 Study Did Not Meet Primary Endpoint

       Company to Discontinue Current Nolasiban IVF Program   Geneva, Switzerland and Boston, MA – November 7, 2019 – ObsEva SA (NASDAQ:OBSV), a biopharmaceutical company developing and commercializing novel therapies

  16. ObsEva SA to Hold Conference Call to Discuss IMPLANT 4 Trial Results and Third Quarter 2019 Financial and Business Update on November 7, 2019

      Geneva, Switzerland and Boston, MA –November 6, 2019 - ObsEva SA (NASDAQ:OBSV), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced that

  17. ObsEva SA to Hold Conference Call to Discuss IMPLANT 4 Trial Results and Third Quarter 2019 Financial and Business Update on November 7, 2019

      Geneva, Switzerland and Boston, MA –November 6, 2019 - ObsEva SA (NASDAQ:OBSV), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced that

  18. ObsEva SA to Participate in Upcoming Investor Conferences

    Geneva, Switzerland and Boston, MA – November 6, 2019 - ObsEva SA (NASDAQ:OBSV), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced that

  19. ObsEva SA to Participate in Upcoming Investor Conferences

    Geneva, Switzerland and Boston, MA – November 6, 2019 - ObsEva SA (NASDAQ:OBSV), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced that

  20. ObsEva SA to Hold Third Quarter 2019 Financial Results and Business Update Call on November 11, 2019

      Geneva, Switzerland and Boston, MA –November 4, 2019 - ObsEva SA (NASDAQ:OBSV), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious

  21. ObsEva Announces Clearance to Initiate Pivotal US Phase 3 Clinical Trial (IMPLANT 3) of Nolasiban in Women Undergoing Embryo Transfer Following IVF

      FDA Allows IMPLANT 3 Trial to Begin Geneva, Switzerland and Boston, MA – October 31, 2019 – ObsEva SA (NASDAQ:OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of

  22. ObsEva SA to Present Model-Based Analysis Supporting Clinical Use of Linzagolix at Doses Not Requiring Hormonal Add back Therapy

    Once-daily oral Linzagolix doses of 75 mg and 100 mg without hormonal add-back therapy could lead to symptom relief of endometriosis-association pain and heavy bleeding from uterine fibroids while maintaining bone

  23. ObsEva SA to Present Model-Based Analysis Supporting Clinical Use of Linzagolix at Doses Not Requiring Hormonal Add back Therapy

    Once-daily oral Linzagolix doses of 75 mg and 100 mg without hormonal add-back therapy could lead to symptom relief of endometriosis-association pain and heavy bleeding from uterine fibroids while maintaining bone

  24. ObsEva SA to Present New Clinical Data on its Lead Compounds Nolasiban and Linzagolix at the 75th Annual ASRM Meeting in Philadelphia, PA

    Geneva, Switzerland and Boston, MA –October 9, 2019- ObsEva SA (NASDAQ:OBSV), a Swiss  clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious

  25. ObsEva SA to Present New Clinical Data on its Lead Compounds Nolasiban and Linzagolix at the 75th Annual ASRM Meeting in Philadelphia, PA

    Geneva, Switzerland and Boston, MA –October 9, 2019- ObsEva SA (NASDAQ:OBSV), a Swiss  clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious

  26. ObsEva SA to Participate in Cantor Global Healthcare Conference October 2-4, 2019

    Geneva, Switzerland and Boston, MA – September 27, 2019 - ObsEva SA (NASDAQ:OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious

  27. ObsEva SA to Participate in Cantor Global Healthcare Conference October 2-4, 2019

    Geneva, Switzerland and Boston, MA – September 27, 2019 - ObsEva SA (NASDAQ:OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious

  28. ObsEva announces new composition of its Executive Committee

    Geneva, Switzerland and Boston, MA – September 11, 2019 – ObsEva SA (NASDAQ:OBSV), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious

  29. ObsEva announces new composition of its Executive Committee

    Geneva, Switzerland and Boston, MA – September 11, 2019 – ObsEva SA (NASDAQ:OBSV), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious

  30. ObsEva Reports New Clinical Evidence of Nolasiban Mechanism of Action, Supporting Its Potential to Increase Live Birth Rate Following Embryo Transfer in IVF

    Results show decreased uterine contractions, increased endometrial blood flow and gene expression relevant for uterine receptivity to implantation 4Q:19 Read-out confirmed for Phase 3 IMPLANT 4 trial of ObsEva's novel

  31. ObsEva Reports New Clinical Evidence of Nolasiban Mechanism of Action, Supporting Its Potential to Increase Live Birth Rate Following Embryo Transfer in IVF

    Results show decreased uterine contractions, increased endometrial blood flow and gene expression relevant for uterine receptivity to implantation 4Q:19 Read-out confirmed for Phase 3 IMPLANT 4 trial of ObsEva's novel

  32. ObsEva SA to Participate in Upcoming Investor Conferences

    Geneva, Switzerland and Boston, MA – August 30, 2019 - ObsEva SA (NASDAQ:OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions

  33. ObsEva SA to Participate in Upcoming Investor Conferences

    Geneva, Switzerland and Boston, MA – August 30, 2019 - ObsEva SA (NASDAQ:OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions